Logo
x

Search

Subscribe Now

Multiple Cancer

Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications

Apobiologix's Bambevi (biosimilar- bevacizumab) Receives Health Canada Approval for Multiple Cancer Indications

  • September 27, 2021
CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications

CStone Signs a License Agreement with LegoChem for LCB71 to Treat Multiple Cancer Indications

  • October 29, 2020
Centus Biotherapeutics' Equidacent (bevacizumab- biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer Indications

Centus Biotherapeutics' Equidacent (bevacizumab- biosimilar) Receives CHMP's Positive Opinion for the Treatment of Multiple Cancer...

  • July 27, 2020
Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications

Thermo Fisher Scientific Collaborates with Janssen to Co-Develop CDx for Multiple Cancer Indications

  • March 12, 2020
Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and...

  • March 6, 2020
MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

    MSD Collaborates with I-Mab to Evaluate Keytruda + TJC4 for Multiple Cancer Indications

    • September 24, 2019
    Teva Canada

      Teva Canada's Herzuma (biosimilar- trastuzumab) Receives Health Canada Approval for Multiple Cancer Indications

      • September 12, 2019
      Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers

        Celgene Signs an Option to License Agreement with Immatics to Develop Novel Adoptive Cell Therapies Targeting Multiple Cancers

        • August 29, 2019
        Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers

          Celgene Collaborates with Presage to Evaluate Therapies with its CIVO Technology for Multiple Cancers

          • May 3, 2019
          Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

            Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

            • August 28, 2018
            Image

            Incisive News in 3 Shots.

            Contact Us

            Our Information

            Follow Us

            Copyright © 2025 PharmaShots - All Rights Reserved.